An immunoinhibitory receptor, Allergin-1 is the target molecule for treatment of allergic asthma
Project/Area Number |
15K15319
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Respiratory organ internal medicine
|
Research Institution | University of Tsukuba |
Principal Investigator |
TAHARA Satoko 筑波大学, 生命領域学際研究センター, 講師 (20360589)
|
Project Period (FY) |
2015-04-01 – 2017-03-31
|
Project Status |
Completed (Fiscal Year 2016)
|
Budget Amount *help |
¥3,640,000 (Direct Cost: ¥2,800,000、Indirect Cost: ¥840,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥2,210,000 (Direct Cost: ¥1,700,000、Indirect Cost: ¥510,000)
|
Keywords | 喘息 / アラジン-1 / House dust mite / アレルギー性喘息 / House Dust Mite |
Outline of Final Research Achievements |
Allergin-1 is an inhibitory immunoglobulin-like receptor bearing immunoreceptor tyrosine-based inhibitory motif (ITIM) in its cytoplasmic region. Allergin-1 inhibits house dust mite-induced serum IgE elevation, airway eosinophilia, and airway hyperreactivity (AHR), therefore, Allergin-1 may be a target molecule for treatment of allergic asthma. In this proposal, a phospholipid liposome was used to treat the HDM-induced allergic asthma. Because, one of the phospholipid has an ability to bind to Allergin-1. However, in the HDM-induced asthma model, not only Allergin-1-binding phospholipid, but also phosphatidylcholine, which does not bind to Allergin-1 inhibited the AHR.
|
Report
(3 results)
Research Products
(12 results)
-
-
-
[Journal Article] Apoptotic epithelial cells control the abundance of Treg cells at barrier surfaces2016
Author(s)
Nakahashi-Oda C, Udayanga KGS, Nakamura Y, Nakazawa Y, Miki H, Iino S, Tahara-Hanaoka S, Shibuya K, Shibuya A.
-
Journal Title
Nature Immunol, 17(4):441-453, 2016
Volume: 17
Issue: 4
Pages: 441-453
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-